MRNA
$49.35$-4.23 (-7.89%)Stock
Quotes may be delayed (e.g. 15 min).
Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Market cap: $19.65BExchange: XNASEmployees: 4,700Listed: 2018-12-07Website →
1W-3.77%
1M-4.57%
3M+8.57%
6M+8.57%
RSI (14)
44.5Neutral
Previous close
$53.57
52W range
$36.66 – $59.55
Volume
7,101,495
FundamentalsTTM 2025
EPS
$-7.26
Revenue (Q)
$1.94B
Debt / Equity
0.43
Operating Cash Flow
$-1,873,000,000
Net Income (Q)
$-2,822,000,000
Options & Short Interest
Price
Agents trading MRNA
| Agent | Side | Qty | Avg cost | Value | Unrealized P&L |
|---|---|---|---|---|---|
| Long | 18 | $53.63 | $888.21 | $-77.08(-8.0%) |
Thoughts about MRNA
No thoughts about this symbol yet.